Hepatitis C: sociodemographic and clinical profile of patients treated with direct-acting antivirals in a pharmaceutical office

To report the sociodemographic and clinical profile of patients treated with direct-action antivirals (DAAs). Patients infected with hepatitis C virus in current treatment were followed up in a pharmaceutical office. Sociodemographic, clinical and medicines uses characteristics were obtained. A tot...

Full description

Bibliographic Details
Published in:	Acta Scientiarum. Health Sciences
Main Authors:	Karem Aline Pegoraro, Edson Luiz Folador, Dennis Armando Bertolini, Angela Maria Campagna
Format:	Article
Language:	English
Published:	Universidade Estadual de Maringá 2023-11-01
Subjects:	HCV; antivirals agents; direct-acting antivirals; pharmaceutical services; genotype.
Online Access:	https://periodicos.uem.br/ojs/index.php/ActaSciHealthSci/article/view/62343

Similar Items

Effect of Direct-Acting Antivirals on Lipid and Glucose Metabolism in Chronic HCV Patients
by: Mohammed Mohammed, et al.
Published: (2019-07-01)

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01)

Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis
by: Liwei Zhuang, et al.
Published: (2021-07-01)

Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection
by: El-Araby Mohamed Ibrahim Shalaby, et al.
Published: (2023-06-01)

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
by: Christopher Dietz, et al.
Published: (2022-06-01)

Gender as a factor affecting NK cell activity in patients successfully treated for chronic hepatitis C with direct-acting antivirals
by: Agata Zientarska, et al.
Published: (2021-12-01)

Genotype distribution, intravenous drug use rates and direct-acting antiviral treatment results in prisoner hepatitis C patients
by: Ö. Şahin, et al.
Published: (2023-04-01)

Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study
by: Mehdi Kashani, et al.
Published: (2024-10-01)

A study on the prevalence of HCV genotypes and the effect of direct-acting antiviral therapy on clinical and laboratory parameters in HCV-Infected patients at a tertiary care center in North India
by: S Muhammed Shahanas, et al.
Published: (2024-01-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

Impact of hepatitis C virus genotype on the efficacy of the direct-acting antivirals in chronic kidney disease patients in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-05-01)

Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis
by: Pooja Devan, et al.
Published: (2023-06-01)

Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients
by: Asmaa M. Elbrolosy, et al.
Published: (2021-03-01)

Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt—case study
by: Mahmoud H. Teaima, et al.
Published: (2021-12-01)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
by: Luca Rinaldi, et al.
Published: (2019-08-01)

CIRCULATING MIRNA-122, MIRNA-155, AND MIRNA- 200 AS PREDICTORS FOR HEPATOCELLULAR CARCINOMA OCCURRENCE IN EGYPTIAN PATIENTS WITH HEPATITIS C RELATED LIVER CIRRHOSIS TREATED WITH DIRECT ACTING ANTIVIRAL DRUGS
by: Hanan Nafeh, et al.
Published: (2024-06-01)

Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report
by: Michiko Shimada, et al.
Published: (2017-03-01)

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients
by: Sonia Younas, et al.
Published: (2021-10-01)

Serum retinol-binding protein 4 as a predictor of fibrosis regression and response to direct-acting antiviral drugs in chronic hepatitis C virus patients
by: Hany Samir Rasmy, et al.
Published: (2023-03-01)

The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients
by: Meng-Yu Ko, et al.
Published: (2025-02-01)

Risk of adverse outcomes following treatment with direct acting antiviral drugs in HCV infected patients with liver cirrhosis
by: Hafiza Arooba Riaz, et al.
Published: (2023-05-01)

Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy
by: Chun-Hsien Chen, et al.
Published: (2023-01-01)

ASSESSMENT OF CARDIAC FUNCTIONS IN EGYPTIAN CHRONIC HEPATITIS C PATIENTS BEFORE AND AFTER TREATMENT WITH DIRECTLY ACTING ANTIVIRALS
by: ESLAM S. MOHAMED, et al.
Published: (2021-08-01)

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Efficacy of Different Combinations of Direct-Acting Antivirals Against Different Hepatitis C Virus-Infected Population Groups: An Experience in Tertiary Care Hospitals in West Bengal, India
by: Sagnik Bakshi, et al.
Published: (2025-02-01)

The Natural History of Hepatitis C Virus Infection and Disease in the Era of Curative Therapy with Direct-Acting Antivirals
by: Maurizia Rossana Brunetto, et al.
Published: (2025-02-01)

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination
by: Dorota Zarębska-Michaluk, et al.
Published: (2024-10-01)

Weight Gain and Increased Body Mass Index in Patients with Hepatitis C after Eradication Using Direct-Acting Antiviral Therapy in Taiwan
by: Chun-Hsien Chen, et al.
Published: (2024-01-01)

Treatment of hepatitis C virus infection: From therapy with interferon to direct-acting antivirals
by: Laura Lopera, et al.
Published: (2023-01-01)

Identification and management of contraindicated drug–drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy
by: Meng Hsuan Kuo, et al.
Published: (2022-01-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis
by: Shahd Hamran, et al.
Published: (2025-04-01)

HEPATOCELLULAR CARCINOMA INCIDENCE IN HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS AND ITS RELATIONSHIP TO HEPATIC FIBROSIS STAGE
by: AYMAN G. A. DAWOD, et al.
Published: (2021-08-01)

Effect of direct-acting antivirals on the titers of human pegivirus 1 during treatment of chronic hepatitis C patients
by: Ulrik Fahnøe, et al.
Published: (2024-09-01)

Telemedicine and hybrid engagement models facilitate hepatitis C cascade of care during periods of healthcare disruption
by: Sabrina Fan, et al.
Published: (2026-01-01)

Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States
by: Haesuk Park, et al.
Published: (2023-04-01)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
by: Hassan AM, et al.
Published: (2018-06-01)

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
by: Tommaso Lorenzo Parigi, et al.
Published: (2019-12-01)

The impact of antiviral therapy on hepatocellular carcinoma epidemiology
by: Massimo Colombo, et al.
Published: (2018-01-01)